Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹607.00
₹14.40(2.38%)
At close: 4:00 PM EDT
₹607.00
₹14.40(2.38%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹1,095.65
Previous CloseN/A
Volume305.42K
Average Volume (3M)65.92K
Market Cap
₹199.56B
Enterprise Value₹74.34B
Total Cash (Recent Filing)₹451.80M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)67.2
Beta0.69
Next Earnings
Nov 06, 2026EPS Estimate
3.9Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)15.20
Shares Outstanding195,581,820
10 Day Avg. Volume72,292
30 Day Avg. Volume65,925
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.08
Revenue Forecast (FY)₹19.09B
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings RecoveryThe sharp rebound in revenue and earnings indicates improved commercial performance after a weaker period. If sustained, stronger product demand and operating execution can expand the company’s financial capacity, support reinvestment, and improve resilience over the next several quarters.
Improved Balance SheetLower leverage gives Shilpa Medicare greater financial flexibility while it funds pharmaceutical development, manufacturing, and commercialization. A stronger equity base and steadily expanding assets also reduce balance-sheet strain and improve its ability to support growth without excessive borrowing.
Strong FY2026 ProfitabilityThe substantial improvement in net, EBIT, and EBITDA margins shows that the earnings recovery was accompanied by stronger operating profitability. This creates greater internal capacity for research, production, and market expansion, although maintaining these margins will remain important.
Bears Say
Persistent Negative Free Cash FlowRecurring negative free cash flow means reported profits have not translated into surplus cash after investment needs. This can increase dependence on financing or working-capital management, constrain discretionary investment, and weaken the durability of the recent earnings recovery.
Weak Cash ConversionWeak conversion of accounting earnings into cash raises questions about how efficiently the business turns profitability into funding resources. Over the next several quarters, continued modest cash coverage could limit flexibility for capacity expansion, product development, or other strategic priorities.
Volatile Profitability And ReturnsThe margin decline and history of weak or negative returns indicate that profitability has not yet demonstrated consistent stability across cycles. Earnings may therefore remain sensitive to product mix and cost structure, making sustained shareholder returns less predictable despite FY2026 improvement.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹1095.65 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹199.56B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Nov 06, 2026 which is in 25 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Aug 05, 2026. The company reported ₹5.18 earnings per share for the quarter, beating the consensus estimate of ₹4 by ₹1.18.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.6 which represents an annual dividend yield of 0.11%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate is 3.9.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹5.18 in its last earnings report, beating expectations of ₹4. Following the earnings report the stock price went up 11.251%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―